Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery

• Status: Completed
• Trial end date: 2021-12-10
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to evaluate the short-term effects and safety of prophylactic intra-vitreal injection of triamcinolone-moxifloxacin combination after cataract surgery. 84 patients underwent cataract surgery associated with intra-vitreal injection of triamcinolone-moxifloxacin combination after surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emad Abdel Aal Saliem
• Treatments: Moxifloxacin; Triamcinolone

Criteria

Inclusion criteria: Patients underwent uncomplicated cataract surgery with:

• A significant cataract.

• Good control of diabetes mellitus (DM) and hypertension (HPT) if present.

• Visual acuity not less than hand movement (HM).

Exclusion criteria:

The followings were the exclusion criteria:

• The use of systemic or topical steroids, topical ophthalmic antibiotics, or non-steroidal anti-inflammatory drugs (NSAIDs) for one week before operation.

• Make an additional procedure at the same time with cataract surgery.

• Those with uncontrolled glaucoma or with marked visual field defect .

• Those with a significant macular edema due to DM, HPT, retinal vein occlusion (CRVO) or due to any previous inflammatory condition.

• Those with blepharitis or any other local disease interfering with surgical intervention or affecting on the surgical outcome.

• Occurrence of intraoperative complications as posterior capsular rupture or postoperative complications as retained lens fragment.